Related Experiment Video
Updated: Nov 24, 2025

Author Spotlight: Finding New Therapeutic Targets for Malignant Peripheral Nerve Sheath Tumor Through Genome-Scale shRNA Screens
Published on: August 25, 2023
A Multipronged Screening Approach Targeting Inhibition of ETV6 PNT Domain Polymerization
Chloe A N Gerak1, Si Miao Zhang1, Aruna D Balgi1
1Department of Biochemistry and Molecular Biology, University of British Columbia, Vancouver, BC, Canada.
Abstract:
ETV6 is an ETS family transcriptional repressor for which head-to-tail polymerization of its PNT domain facilitates cooperative binding to DNA by its ETS domain. Chromosomal translocations frequently fuse the ETV6 PNT domain to one of several protein tyrosine kinases. The resulting chimeric oncoproteins undergo ligand-independent self-association, autophosphorylation, and aberrant stimulation of downstream signaling pathways, leading to a variety of cancers. Currently, no small-molecule inhibitors of ETV6 PNT domain polymerization are known and no assays targeting PNT domain polymerization have been described. In this study, we developed complementary experimental and computational approaches for identifying such inhibitory compounds. One mammalian cellular approach utilized a mutant PNT domain heterodimer system covalently attached to split Gaussia luciferase fragments. In this protein-fragment complementation assay, inhibition of PNT domain heterodimerization reduces luminescence. A yeast assay took advantage of activation of the reporter HIS3 gene upon heterodimerization of mutant PNT domains fused to DNA-binding and transactivation domains. In this two-hybrid screen, inhibition of PNT domain heterodimerization prevents cell growth in medium lacking histidine. The Bristol University Docking Engine (BUDE) was used to identify virtual ligands from the ZINC8 library predicted to bind the PNT domain polymerization interfaces. More than 75 hits from these three assays were tested by nuclear magnetic resonance spectroscopy for binding to the purified ETV6 PNT domain. Although none were found to bind, the lessons learned from this study may facilitate future approaches for developing therapeutics that act against ETV6 oncoproteins by disrupting PNT domain polymerization.
Insights
Researchers developed new experimental and computational assays to find inhibitors of ETV6 PNT domain polymerization, a key process in cancer development. While no inhibitors were identified, the study provides valuable insights for future drug discovery targeting ETV6 oncoproteins.
Area of Science:
- Molecular Biology
- Biochemistry
- Cancer Research
Background:
- ETV6 is a transcriptional repressor whose PNT domain polymerization is crucial for DNA binding.
- Chromosomal translocations involving ETV6 create chimeric oncoproteins driving various cancers.
- No small-molecule inhibitors or assays targeting ETV6 PNT domain polymerization are currently available.
Purpose of the Study:
- To develop novel experimental and computational assays for identifying inhibitors of ETV6 PNT domain polymerization.
- To screen for compounds that disrupt the polymerization process crucial for ETV6-driven oncogenesis.
Main Methods:
- Developed a mammalian cell-based protein-fragment complementation assay using split Gaussia luciferase.
- Established a yeast two-hybrid assay utilizing the HIS3 reporter gene.
- Employed the Bristol University Docking Engine (BUDE) for virtual screening of the ZINC8 library.
- Validated hits using nuclear magnetic resonance (NMR) spectroscopy.
Main Results:
- Successfully established functional mammalian and yeast-based assays for ETV6 PNT domain polymerization.
- Identified over 75 potential ligands through computational screening.
- NMR spectroscopy confirmed that none of the tested compounds directly bind to the purified ETV6 PNT domain.
Conclusions:
- The developed assays provide a foundation for future screening of ETV6 PNT domain polymerization inhibitors.
- This study offers valuable insights that may guide the development of novel therapeutics targeting ETV6 oncoproteins.
- Further research is needed to identify effective inhibitors that disrupt ETV6 PNT domain polymerization for cancer treatment.

